Search PubMed⌕ Search

Biomedical subjects

G Wiedermann

Publications and source records attributed to G Wiedermann.

189 records · Page 11Linked to original sources
PubMedDate not supplied

Plasmodium falciparum: susceptibility in vitro and in vivo to chloroquine and sulfadoxine-pyrimethamine in Ghanaian schoolchildren.

In Ghana, resistance of Plasmodium falciparum to chloroquine was observed for the first time in 1986. By the end of 1991 it had reached a high frequency and a substantial degree. A combined study in vivo and in vitro of the response of P. falciparum to chloroquine and sulfadoxine/pyrimethamine was carried out in Madina, Accra, in the coastal area of Ghana, late in 1991. 96 valid tests in vivo were performed with children and adolescents. There were 52 successful tests in vitro with chloroquine, and 52 with sulfadoxine/pyrimethamine. 45% of the chloroquine tests in vivo and 37% of the sulfadoxine/pyrimethamine tests in vivo indicated RII/RIII resistance. Results in vivo and in vitro were significantly correlated. The presence of RIII responses, 9% with chloroquine and 14% with sulfadoxine/pyrimethamine, indicates a need for third-line antimalarial drugs, the unregulated use of which may entail the risk of early and rapid occurrence of multi-resistance.

Adolescent↗
PubMedDate not supplied

Chloroquine resistance of Plasmodium falciparum: a biological advantage?

The response in vitro of Plasmodium falciparum to chloroquine, mefloquine and quinine was studied in a hyperendemic peri-urban area of Accra, Ghana, during the fourth quarter of 1991, yielding a total of 159 valid tests. Schizont maturation in drug-free controls and effective chloroquine concentrations were strongly correlated. This was not seen with mefloquine or quinine. Higher mean parasitaemia in untreated oligo-symptomatic carriers of overtly chloroquine-resistant P. falciparum than in carriers of more sensitive parasites was another indication of higher viability and biological advantage of chloroquine-resistant P. falciparum that may conceivably have clinical implications.

Adolescent↗
PubMedDate not supplied

Inactivated hepatitis A vaccine: long-term antibody persistence.

During the clinical development of safe, well tolerated and immunogenic vaccines against hepatitis A the persistence of protective antibodies was estimated, based on relatively short observation periods of 18 months to 3 years. We report here on longterm persistence of antibodies in volunteers who participated in one of the early clinical trials on inactivated hepatitis A candidate vaccines. In a randomized trial three groups of altogether 110 healthy adults, initially hepatitis A virus (HAV) seronegative persons were vaccinated with an inactivated hepatitis A vaccine according to the schedule 0-1-2-12 months. One group received 180 ELISA units, one group 360, and one 720 ELISA units per dose. Blood samples were taken prior to the first vaccination and at months 1, 2, 3, 4, 6, 12, 13, 18, 24, 36 and 84. The decrease of antibodies was characterized by two disappearance rates: a rapidly decreasing component and a slower decreasing one becoming predominant ca 12 months after booster vaccination. The disappearance of antibodies could be described by a two-component model which holds for t > or = 13 months. The estimated disappearance rates for the slow component (annual decrease) was found to be 11 and 13% for the 180 and 360 El. U groups, respectively (the 720 El. U group showed no decline, which was probably due to the small sample size). The estimated persistence of antibodies within protective range varied between 24 and 47 years depending on individual titres reached at month 13 and vaccination dose.

Adult↗
PubMedDate not supplied

Molecular characterization of the cDNA coding for translation elongation factor-2 of pathogenic Entamoeba histolytica.

To investigate the humoral immune response of patients with amoebic dysentry against Entamoeba histolytica, immunoglobulin G (IgG)-immunopositive cDNA clones from the pathogenic strain SFL-3 were examined. A large part of the IgG-positive cDNA clones obtained with one serum encoded highly conserved intracellular proteins. A clone was found that was homologous to translation elongation factor-2 (EF-2). Sequence analysis of the EF-2 cDNA showed 63.6% amino acid sequence identity with the human homologue. The deduced protein sequence has a length of 840 amino acid residues with a molecular mass of 93.3 kD. The 3' and 5' untranslated regions of the mRNA are relatively short as shown for other genes of E. histolytica. A genomic clone was used to analyze the region upstream of the translation initiation codon. The codon distribution of EF-2 and other published E. histolytica sequences reflects the high A/T content. The codons for different amino acids are biased to a widely differing extent.

Amino Acid Sequence↗